Travere Therapeutics, Inc. today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 shares of its ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: ...
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 ...
This rare disease therapeutics specialist reported a notable insider sale amid a year of strong share price gains and ...
Guggenheim analyst Vamil Divan maintained a Buy rating on Insmed today and set a price target of $230.00. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful investi ...
Quanterix Corporation , a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial Officer ("CFO" ...
New understanding about the pathophysiology of the condition, along with new clinical trial endpoints for approval, have ...
Researchers report the impact of sparsentan vs irbesartan on proteinuria in patients with focal segmental glomerulosclerosis.
Ligand Pharmaceuticals (NASDAQ:LGND) reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from ...
Over the last 7 days, the United States market has risen 3.2%, contributing to a 31% increase over the past year, with ...
Climb Bio Inc.’s stock-tickling event May 5 highlighting Fc-enhanced monoclonal antibody (mAb) budoprutug, followed two days later by a financial update, has kept Wall Street buzzing. Mizuho analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results